Tobacco smoking is the number one health problem accounting for more illnesses and deaths in the US than any other factor. Despite efficacy of some current pharmacotherapies (i.e., nicotine replacement and bupropion), relapse rates continue to be high, indicating that novel medications are needed. Research in the current application proposes to develop a new class of subtype-selective nicotinic receptor (nAChR) antagonists as therapeutic agents with efficacy for tobacco use cessation and for treatment of nicotine dependence. As much as tobacco use behavior and nicotine addiction have links to depression, these novel drug candidates may also prove to be new treatments for depression. Based on the observations that the bupropion acts as a nAChR antagonist and that the nonselective nAChR antagonist, mecamylamine, has some efficacy as a tobacco use cessation agent, but is limited by its peripherally-mediated side-effect of constipation, we predict that the subtype-selective nAChR antagonists, which we propose to develop, may have therapeutic advantages and efficacy as tobacco use cessation agents in the treatment of nicotine addiction. We hypothesize that quaternizing the pyridine-N atom of the nicotine molecule with a lipophillic N-substituent to afford N-nicotinium analogs and/or by connecting these quaternary ammonium moieties with a lipophillic linker to afford N,N'-bis-analogs will result in subtype-selective nAChR antagonists, which will inhibit either nicotine-evoked dopamine, norepinephrine or serotonin release, and thus, inhibit nicotine-induced behaviors, indicating their potential as nicotine addiction treatments. Brain bioavailability, pharmacokinetics and metabolism of the lead candidates will also be evaluated. Comparison of results using native and recombinant nAChRs will provide new insights into the subunit composition of nAChRs mediating these functions. Drug candidates will be assessed for their ability to decrease nicotine self-administration, to decrease nicotine-induced reinstatement of nicotine seeking behavior, and to precipitate withdrawal in nicotine-dependent animals. Thus, an integrative approach (i.e., medicinal chemistry, pharmacokinetics, metabolism, pharmacology, psychology and neuroscience) will be used to increase our understanding of the underlying mechanisms of tobacco use and nicotine addiction, with focus on pharmacotherapeutic candidate development.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19DA017548-05
Application #
7262407
Study Section
Special Emphasis Panel (ZMH1-BRB-S (08))
Program Officer
Rapaka, Rao
Project Start
2003-09-30
Project End
2009-06-30
Budget Start
2007-07-01
Budget End
2009-06-30
Support Year
5
Fiscal Year
2007
Total Cost
$1,290,333
Indirect Cost
Name
University of Kentucky
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
939017877
City
Lexington
State
KY
Country
United States
Zip Code
40506
Maggio, Sarah E; Saunders, Meredith A; Nixon, Kimberly et al. (2018) An improved model of ethanol and nicotine co-use in female P rats: Effects of naltrexone, varenicline, and the selective nicotinic ?6?2* antagonist r-bPiDI. Drug Alcohol Depend 193:154-161
Maggio, Sarah E; Saunders, Meredith A; Baxter, Thomas A et al. (2018) Effects of the nicotinic agonist varenicline, nicotinic antagonist r-bPiDI, and DAT inhibitor (R)-modafinil on co-use of ethanol and nicotine in female P rats. Psychopharmacology (Berl) 235:1439-1453
Holt, J Chris; Kewin, Kevin; Jordan, Paivi M et al. (2015) Pharmacologically distinct nicotinic acetylcholine receptors drive efferent-mediated excitation in calyx-bearing vestibular afferents. J Neurosci 35:3625-43
Beckmann, Joshua S; Meyer, Andrew C; Pivavarchyk, M et al. (2015) r-bPiDI, an ?6?2* Nicotinic Receptor Antagonist, Decreases Nicotine-Evoked Dopamine Release and Nicotine Reinforcement. Neurochem Res 40:2121-30
Crooks, Peter A; Bardo, Michael T; Dwoskin, Linda P (2014) Nicotinic receptor antagonists as treatments for nicotine abuse. Adv Pharmacol 69:513-51
De Biasi, M; McLaughlin, I; Perez, E E et al. (2014) Scientific overview: 2013 BBC plenary symposium on tobacco addiction. Drug Alcohol Depend 141:107-17
Nickell, Justin R; Grinevich, Vladimir P; Siripurapu, Kiran B et al. (2013) Potential therapeutic uses of mecamylamine and its stereoisomers. Pharmacol Biochem Behav 108:28-43
Holtman, Joseph R; Dwoskin, Linda P; Dowell, Cheryl et al. (2011) The novel small molecule ?9?10 nicotinic acetylcholine receptor antagonist ZZ-204G is analgesic. Eur J Pharmacol 670:500-8
Zheng, Guangrong; Zhang, Zhenfa; Dowell, Cheryl et al. (2011) Discovery of non-peptide, small molecule antagonists of ?9?10 nicotinic acetylcholine receptors as novel analgesics for the treatment of neuropathic and tonic inflammatory pain. Bioorg Med Chem Lett 21:2476-9
Zhang, Zhenfa; Dwoskin, Linda P; Crooks, Peter A (2011) Expeditious synthesis of cis-1-methyl-2, 3,3a,4,5,9b-hexahydro-1H-pyrrolo-[3,2h]isoquinoline / [2,3-f]quinoline via azomethine ylide-alkene [3+2] cycloaddition. Tetrahedron Lett 52:2667-2669

Showing the most recent 10 out of 65 publications